Gilead Signs Royalty-Free Voluntary Licensing Agreements for 6 HIV Prep Generics

 – License for Companies to Manufacture and Supply High-Quality, Low-Cost Versions of Lenacapavir for 120 Primarily Low- and Lower-Middle Income Countries –

– Gilead Plans to Price Product at No Profit to the Company and Supply Lenacapavir Until Generic Manufacturers Fully Support Demand –

– Agreements Also Cover Lenacapavir for HIV Treatment in Heavily Treatment-Experienced Adults with Multi-Drug Resistant HIV –

https://www.businesswire.com/news/home/20241001289353/en